BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 27,400 shares, an increase of 14.2% from the November 30th total of 24,000 shares. Based on an average daily trading volume, of 88,900 shares, the days-to-cover ratio is currently 0.3 days.

BrainsWay Stock Up 2.3 %

Shares of NASDAQ BWAY traded up $0.21 during midday trading on Tuesday, hitting $9.43. The stock had a trading volume of 38,503 shares, compared to its average volume of 91,637. The stock has a 50 day simple moving average of $9.77 and a 200-day simple moving average of $8.37. The company has a market capitalization of $177.41 million, a PE ratio of 94.31 and a beta of 1.23. BrainsWay has a 1 year low of $4.61 and a 1 year high of $10.98.

BrainsWay (NASDAQ:BWAY - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The firm had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. During the same period in the prior year, the company earned ($0.01) EPS. As a group, analysts expect that BrainsWay will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BrainsWay

A number of institutional investors and hedge funds have recently bought and sold shares of BWAY. JPMorgan Chase & Co. lifted its stake in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after purchasing an additional 11,221 shares in the last quarter. Rhumbline Advisers boosted its stake in BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock worth $110,000 after buying an additional 1,695 shares during the last quarter. Perritt Capital Management Inc purchased a new stake in BrainsWay in the 2nd quarter valued at $121,000. Good Life Advisors LLC increased its stake in shares of BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock worth $516,000 after acquiring an additional 22,080 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company's stock worth $1,567,000 after acquiring an additional 84,371 shares during the period. 30.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on BWAY shares. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of BrainsWay in a research report on Monday, December 23rd. Northland Securities increased their price objective on shares of BrainsWay from $11.00 to $12.50 and gave the company an "outperform" rating in a report on Thursday, October 3rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.